Tag: Nanolek

NANOLEK is a Russian biopharmaceutical company with its own high-tech complete cycle production corresponding to the GMP and ISO standards and with RUSNANO among the shareholders.

NANOLEK specializes in the production of import-substituting and innovative pharmaceuticals, both in-house developed and invented with the help of international partners, with a focus on the prevention and treatment of socially significant diseases.

Biomedical complex “NANOLEK” includes three independent production buildings. The plant was built and designed from the ground up under the priority areas of the product portfolio:
1) production of solid dosage forms (antiretroviral therapy, oncology and cardiovascular diseases);
2) biotechnology production in syringes and vials.

From the localization of import substituted drugs to the manufacture of domestic innovative drug development.

Nanolek is implementing its strategy in two stages, while adhering to state priorities for the development of the domestic pharmaceutical industry and the Pharma-2020 strategy.

At the first stage (2012-2017), the NANOLEK’s activity was focused on the priorities of the state policy in the field of import substitution and was aimed at localization on the basis of the production site of the company in the Kirov region producing the most popular high-tech medicines, including those never-before-produced in the Russian Federation.

The next stage (2018-2022) will be introducing to market innovative high-tech in-house developed products, the work on which is being conducted in association with leading Russian research institutes and leading foreign research companies.

NANOLEK will cover the needs for inactivated polio vaccine in Russia

nanolek
Polymilex, an inactivated polio vaccine, is the first IPV fully manufactured in Russia

NANOLEK becomes the first Russian partner of SK Chemicals from Korea

nanolek
NANOLEK announced its cooperation in the area of joint research, development, and manufacturing of vaccines with SK Chemicals

In 2018 Nanolek will fully cover the needs of Russian market in IPV

nanolek
Today the world faces problems in meeting the demand for inactivated polio vaccine (IPV) which can be explained by increased global needs in this medicine

Authorities select pharmaceutical companies for participation in Kirov cluster

The Government of the Kirov region held a meeting of its working group on the formation of industrial cluster

NANOLEK will supply Tepadina to the Russian market

nanolek
NANOLEK announced its cooperation with RIMZER Pharma GmbH (Germany), which will open the door to NANOLEK to distribute Tepadina® (LP-001134 Adienne S.r.l.; INN: thiotepa) in Russia. Thiotepa is used a...

Nacimbio and Nanolek announced cooperation in vaccine manufacturing

nanolek
Nacimbio and Nanolec intend to combine their competencies and efforts in the development and organization of a full technological cycle for manufacturing immunobiological medicines at the facilities o...

Sanofi Pasteur localized the manufacturing of vaccines at NANOLEK site

nanolek
Sanofi Pasteur, a division of Sanofi Group, announced that the company’s pentavalent combination vaccine intended for the Russian market is manufactured on the production site of NANOLEK, an innovativ...

The Director of the Federal Industry Development Fund builds familiarity with “Nanolek” production

nanolek
On January 18, Alexey Komissarov, Director of the Federal Industry Development Fund, paid a working visit to Kirov region. The first production site that he visited was a biomedical complex NANOLEK wh...

NANOLEK is Russia’s first to produce inactivated polio vaccine

Nanolek
On 11th of November, there has been a grand opening of an innovative vaccines and biotechnological production of NANOLEK located in Kirov. The new production is based on the most modern technologies, ...